JAGSNPHARM.BOJAGSNPHARM.BO
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
17.50%
↓ 89% below average
Average (39q)
159.21%
Historical baseline
Range
High:2735.71%
Low:-619.35%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 17.50% |
| Q2 2025 | 63.27% |
| Q1 2025 | -79.32% |
| Q4 2024 | 175.58% |
| Q3 2024 | 112.35% |
| Q2 2024 | 50.00% |
| Q1 2024 | -10.00% |
| Q4 2023 | -78.95% |
| Q3 2023 | 0.00% |
| Q2 2023 | 33.18% |
| Q1 2023 | -27.95% |
| Q4 2022 | -25.19% |
| Q3 2022 | 2735.71% |
| Q2 2022 | 1373.68% |
| Q1 2022 | -99.53% |
| Q4 2021 | -19.52% |
| Q3 2021 | -3.83% |
| Q2 2021 | 34.54% |
| Q1 2021 | -6.28% |
| Q4 2020 | 35.29% |
| Q3 2020 | 59.38% |
| Q2 2020 | 62.71% |
| Q1 2020 | -32.18% |
| Q4 2019 | 12.99% |
| Q3 2019 | 1.32% |
| Q2 2019 | -33.33% |
| Q1 2019 | 70.15% |
| Q4 2018 | -1.47% |
| Q3 2018 | 142.86% |
| Q2 2018 | 159.57% |
| Q1 2018 | 45.35% |
| Q4 2017 | 41.50% |
| Q3 2017 | 8.70% |
| Q2 2017 | -619.35% |
| Q1 2017 | -91.80% |
| Q4 2016 | 1889.47% |
| Q3 2016 | -20.83% |
| Q2 2016 | -68.42% |
| Q1 2016 | 484.62% |
| Q4 2015 | -23.53% |